Deals this week: Protagen, Spring Bank Pharmaceuticals, Iatric Systems
Protagen and Novartis Pharma have entered an agreement to clinically develop a compound for an autoimmune disease.
Pursuant to the agreement, Novartis will be responsible to develop the novel drug candidate using Protagen’s proprietary SeroTag technology.
The agreement enables the two partners to evaluate prediction and patient satisfaction markers for the new drug.
Spring Bank Pharmaceuticals and Arbutus Biopharma Corporation have entered an agreement to advance clinical studies in the chronic Hepatitis B virus.
Under the agreement, the two partners will jointly perform preclinical trials through co-administration of Spring Bank Pharma’s SB 9200 and Arbutus Biopharma’s AB-423.
The agreement enables the two partners to develop a treatment for chronic HBV infection.
Iatric Systems and Hospira have entered an agreement to develop smart pump-EMR interoperability.
Under the agreement, the two companies will develop interoperability between Hospira’s smart infusion devices and Iatric’s Systems Accelero Connect integration software.
The agreement enables the partners to develop smart pump EMR interoperability to enable two-way communications.
Bristol-Myers Squibb and Calithera Biosciences have entered a clinical trial collaboration agreement to develop a novel treatment for renal cell carcinoma.
The two partners will evaluate the efficacy of Bristol Myers Squibb’s Opdivo with Calithera’s CB-839 in a phase ½ clinical trials, as part of the agreement.
The agreement allows the two partners to examine the target immune-suppressive cells in a tumour microenvironment.
Gradalis and Icahn School of Medicine at Mount Sinai have entered a research agreement to further evaluate the scientific understanding of Vigil® Engineered Autologous Tumour Cell treatment.
Gradalis will be responsible to provide funds and clinical research samples to evaluate immune responses generated by the Vigil engineered autologous tumour cell therapy.
The agreement allows the two partners to develop Vigil EATC treatment for different types of cancers.
Revolution Medicines plans to advance its drug discovery and clinical development programme through the funds raised in a series A venture financing round.
The company has raised $25m in the financing round led by Column Group and Third Rock Ventures.
Mesoblast has entered an agreement with Mallinckrodt Pharmaceuticals to negotiate the commercial development of two Mesoblast's Tier 1 product candidates.
The agreement gives Mallinckrodt Pharma an exclusive period of up to nine months to conclude commercial and development agreements for the two product candidates in all territories excluding Japan and China.
Furthermore, it will enable both Mallinckrodt Pharma and Mesoblast to develop cell therapy products MPC-06-ID and MSC-100-IV, which are used for the treatment of chronic low back pain and acute graft versus host diseases respectively.
Mallinckrodt Pharma will buy approximately 2.4 million shares of Mesoblast common stock shares of Mesoblast common stock priced at A$1.47 ($1.07) a share to raise gross proceeds of A$29.58m ($21.37m).
D.Western Therapeutics Institute and the University of Toyama have entered an agreement for the research and development (R&D) of therapeutic agents for retinal degenerative diseases.
D.Western Therapeutics Institute is a biotechnology company, whereas University of Toyama is an educational institute.
Kubota Pharmaceutical Holdings has signed a joint venture (JV) agreement with SBI Holdings for the development of ophthalmic drugs and devices.
Under the agreement, ophthalmology company Kubota Pharma will fund 51% of the JV, while the remaining 49% will be funded by SBI Holdings, a financial services and asset management company.
The agreement will enable the JV to focus on the development of ophthalmic drugs and devices based on mHealth platform, a mobile communications technology aimed at enhancing access to healthcare information, improving distribution of routine and emergency health services, and providing diagnostic services.
Pluristem Therapeutics has entered an agreement with the New York Blood Center (NYBC) for pre-clinical studies of Pluristem Therapeutics' Placental eXpanded (PLX)-R18 cells to enhance the efficacy of umbilical cord blood (UCB) transplantation.
The pre-clinical studies have obtained a conditional award of $0.9m from the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD).
Pursuant to the agreement, Pluristem Therapeutics will provide the PLX-R18 cells, while NYBC will conduct the studies.
US-based drug discovery and development company Sharp Edge Labs and Japanese pharmaceutical company Sumitomo Dainippon Pharma have signed a drug discovery agreement for neurodegenerative disorders.
The latter’s proprietary compound library will be shared with the former for use in their drug discovery platform, to enable identification of lead compounds and potential candidates to be developed for treating neurodegenerative disorders.
APT Therapeutics has signed a worldwide agreement for its innovative human apyrase therapy APT102, targeting thrombotic diseases with AstraZeneca.
AstraZeneca will make upfront cash payment and future payments based on development milestones to APT Therapeutics, in addition to funding all future clinical trials for heart attacks and / or strokes, as part of the agreement.